Compare ARK Genomic Revolution ETF (ARKG) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Atlassian Corporation PLC — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Atlassian Corporation PLC trades at $90.1 (market cap $22.55B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| ARKG | TEAM | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $203.00 |
52-Week Low | $23.09 | $57.15 |
Market Cap | — | $22.55B |
Enterprise Value | — | $22.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Atlassian (TEAM) trades at $88.86, down 2.04% today, with strong technical momentum indicated by bullish moving averages. The company shows accelerating revenue growth reaching $5.22B in 2025, though it remains unprofitable with a -3.5% net margin. Recent earnings beats and cloud revenue growth of 29% in Q3 FY26 demonstrate business momentum, while analyst consensus remains strongly bullish with a $119.93 price target representing 35% upside potential.
TEAM presents a compelling growth story with improving fundamentals and strong analyst support, though profitability challenges and AI disruption risks require monitoring. The stock's current valuation at 3.77x sales appears reasonable given the 30%+ revenue growth trajectory, making it attractive for growth-oriented investors willing to accept near-term losses for long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
